Cambridge Epigenetix – Improving health through measurement of the epigenome


Innovative technology and services for DNA methylation analysis


Our vision is a world where epigenetics helps to tackle the most pressing issues of our time and improves health and wellness for everyone. Here at Cambridge Epigenetix, we believe great things happen when people work together. The biggest leaps in human understanding come from collaboration: when the right specialisms, interests and ambitions combine, the benefits are exponential. 

Our new biomarker discovery and development service puts our expertise at your disposal, so we can enrich your understanding, and vice versa.

We have brought together world-leading experts in epigenetics, genomics and the development of next generation sequencing technology. The company is headquartered in Cambridge, UK, and is financed by leading venture capital companies including GV (Google Ventures), Sequoia Capital,Syncona, New Science Ventures and University of Cambridge.

About Us
TrueMethyl analysis

Our Products


Sufficient for 24 oxidative bisulfite (oxBS) reactions and 24 bisulfite (BS)-only reactions

Learn more


Sufficient for 96 oxidative bisulfite (oxBS) reactions and 96 bisulfite (BS)-only reactions

Learn more


For the preparation of 48 TrueMethyl® converted and indexed DNA libraries for Illumina® sequencing

Learn more

To get the latest news delivered to your inbox, signup below.